The study was conducted in collaboration with the research team Mairena Martin at the University of Castilla La Mancha at Ciudad Real and clinical researchers of the Health Park Sant Joan de Deu at Sant Boi de Llobregat.
Schizophrenia is a serious mental illness. From a clinical point of view is considered grouping several diseases that are not well defined or characterized by biomarkers.
Control of Movement
Barrachina’s team studies the A2A adenosine receptor, which is highly expressed in the basal ganglia at the central nervous system and is involved in the control of movement. Furthermore, this protein inhibits the activity of dopamine D2 receptor, hyperactivated in schizophrenia patients and a typical antipsychotics target.
Barrachina, who works in the Institute of Neuropathology at the Bellvitge Biomedical Research Institute (IDIBELL), explains:
“We studied the post- mortem brains of patients. and we found that 50% had very low levels of adenosine A2A receptor. Interestingly, when comparing these data with clinical information provided by the clinical investigators of the study, we note that these patients had motor disorders. In addition, we identified an epigenetic mechanism associated with the decreased receptor expression.”
According to the researcher, this finding allows to identify a new subset of schizophrenia patients with motor disorders.
This study opens the door to a clinical trial, based on radioimage, which would detect the levels of this protein and identify these patients and also to confirm the results obtained in the postmortem brains of patients. Barrachina team proposes to apply a specific combination therapy of antipsychotics and agonists of A2A adenosine:
“Thus, the activity of adenosine A2A receptor will be favoured, reducing the dose of antipsychotics.”